{"DataElement":{"publicId":"2220357","version":"1","preferredName":"Cetuximab Infusion Reaction Reporting Period Indicator","preferredDefinition":"the indicator that asks whether the patient experienced an infusion reaction to cetuximab during the reporting period.","longName":"CETX_INFRX_RP_PD_IND","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2220355","version":"1","preferredName":"Cetuximab Infusion Reaction Reporting Period","preferredDefinition":"information relating to cetuximab infusion reaction reporting period.","longName":"CETUX_INFUSRX_REP_PD","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2220353","version":"1","preferredName":"Cetuximab Infusion related reaction","preferredDefinition":"A monoclonal antibody specific for the epidermal growth factor receptor (EGFR), a tyrosine kinase that triggers cell division.  Cetuximab binds to and inhibits EGFRs, which are overexpressed on the cell surfaces of many types of tumors.  This agent blocks the tumor growth, invasion, and metastasis associated with the overexpression of cell-surface EGFRs. (NCI04):No value exists.","longName":"C1723:CL049508","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Cetuximab","conceptCode":"C1723","definition":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Infusion related reaction","conceptCode":"CL049508","definition":"No value exists.","evsSource":"NCI_META_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F42AB25E-7A85-1BC3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-12","modifiedBy":"ONEDATA","dateModified":"2005-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207238","version":"1","preferredName":"Reporting Period","preferredDefinition":"The act of providing a short account.:An interval of time. (NCI)","longName":"C25651:C25616","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reporting","conceptCode":"C25651","definition":"The act of providing a short account.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Period","conceptCode":"C25616","definition":"An interval of time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-1D5A-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F42AB25E-7A88-1BC3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2220356","version":"1","preferredName":"Cetuximab Infusion Reaction Reporting Period Indicator","preferredDefinition":"the indicator that asks whether the patient experienced an infusion reaction to cetuximab during the reporting period.","longName":"CETX_INFRX_RP_PD_IND","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"255","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No ","ValueMeaning":{"publicId":"2567170","version":"1","preferredName":"No","longName":"2567170","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Updated to add NCIt concept relationship. Updated VM Short Name to be the Public ID to be consistent with current convention for VM Short Name - DW 10-03-2022","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F49137BA-AADF-152C-E034-0003BA3F9857","beginDate":"2005-04-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-12","modifiedBy":"ONEDATA","dateModified":"2005-04-12","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"2567168","version":"1","preferredName":"Yes","longName":"2567168","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":"12/29/2006 - Updated with NCI Thesaurus definition.","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F49137BA-AAE1-152C-E034-0003BA3F9857","beginDate":"2005-04-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-12","modifiedBy":"ONEDATA","dateModified":"2005-04-12","deletedIndicator":"No"},{"value":"Patient did not receive cetuximab","valueDescription":"Patient did not receive cetuximab","ValueMeaning":{"publicId":"2574517","version":"1","preferredName":"Patient did not receive cetuximab","longName":"2574517","preferredDefinition":"Patient did not receive cetuximab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F022-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-12","modifiedBy":"SHIDED","dateModified":"2005-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F49137BA-AAE4-152C-E034-0003BA3F9857","beginDate":"2005-04-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-12","modifiedBy":"ONEDATA","dateModified":"2005-04-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2188676","version":"1","preferredName":"Indicator","preferredDefinition":"An event, entity or condition that typically characterizes a prescribed environment or situation. Indicators determine or aid in determining whether or not certain stated circumstances exist or criteria are satisfied. (On-line Medical Dictionary)","longName":"Indicator","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E49C180D-8C09-0916-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-09-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-09-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F491080A-1272-0CB3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-12","modifiedBy":"REEVESD","dateModified":"2014-08-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Did the patient experience an","type":"Preferred Question Text","description":"Did the patient experience an infusion reaction to cetuximab during the reporting period","url":null,"context":"CTEP"}],"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F490A893-478C-1691-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-12","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}